EBPMN
Enabling indigenous manufacturing of biosimilars in LMICs can ensure self-sufficiency, control over the value chain, and affordable products, addressing global inequality in access.
The Emerging Biopharmaceutical Manufacturers Network (EBPMN), adopted into the constitution in 2019, has established a framework and workplan to guide its activities. Formally established as an international non-profit association in the Netherlands, the EBPMN Secretariat is now hosted in Butantã in São Paulo, Brazil with its registered headquarters in Mumbai, India and aims to expand biopharmaceutical access in low- and middle-income countries (LMICs) by fostering local manufacturing capacity and promoting sustainable practices, paving the way for a healthier and more equitable world.
Enabling indigenous manufacturing of biosimilars in these countries can ensure self-sufficiency, control over the value chain, and affordable products, addressing global inequality in access.
Bringing affordable biopharmaceuticals to Low- and Middle-Income Countries (LMICs) is a crucial step in improving global healthcare equity. A network of like-minded industrial leaders could make it possible to bridge the gap.
The Emerging Biopharmaceutical Manufacturers Network (EBPMN), adopted into the constitution in 2019, has established a framework and workplan to guide its activities. Formally established as an international non-profit association in the Netherlands, the EBPMN Secretariat is now hosted in Butantã in São Paulo, Brazil with its registered headquarters in Mumbai, India and aims to expand biopharmaceutical access in low- and middle-income countries (LMICs) by fostering local manufacturing capacity and promoting sustainable practises, paving the way for a healthier and more equitable world.
Mission statement
Enhance access to biopharmaceuticals by facilitating local manufacturing capacity in LMICs.
Mission Statement
Enhance access to biopharmaceuticals by facilitating local manufacturing capacity in Low- and Middle-Income Countries.
Value proposition
The annual EBPMN forum will become an excellent opportunity to learn about the latest developments in process development technologies, evolving regulatory pathways, new commercial opportunities to forge partnerships, and product development consortia in the global health space. Entry into the space of biosimilars may be a particular attractive business model for (vaccine) companies with an already existing production infrastructure and technological know-how to serve national, regional or global markets.
An interconnected network composed of leading biopharmaceutical manufacturers holds significant potential to drive growth and innovation within the biotech sector, while also yielding advantages for other manufacturers within the network. By leveraging the collective expertise, resources, and market insights of established industry leaders, this collaborative network can foster an environment conducive to mutual growth and advancement.
Value proposition
To achieve its mission, the Network aspires to become a recognized global platform for public private collaborations between emerging biopharmaceutical manufacturers in LMICs and WHO, regulatory agencies, nongovernmental organizations, academic institutions, biotech and service providers.
The primary aim of the Network is to offer its members up-to-date insights into recent advancements within the realm of biotherapeutics, specifically focusing on biosimilars. These progressions encompass strategic, scientific, technical, and business-related enhancements and prospects. Special attention is given to fostering collaborations for product development, encompassing cooperative efforts in development, commercialization, and the exchange of technological expertise.
The annual EBPMN forum will become an excellent opportunity to learn about the latest developments in process development technologies, evolving regulatory pathways and new commercial opportunities to forge partnerships and product development consortia in the global health space. Entry into the space of biosimilars may be a particular attractive business model for (vaccine) companies with an already existing production infrastructure and technological know-how to serve national, regional or global markets.
An interconnected network composed of leading biopharmaceutical manufacturers holds significant potential to drive growth and innovation within the biotech sector, while also yielding advantages for other manufacturers within the network. By leveraging the collective expertise, resources, and market insights of established industry leaders, this collaborative network can foster an environment conducive to mutual growth and advancement.
